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Readily Accessible sp3-Rich Cyclic Hydrazine Frameworks 
Exploiting Nitrogen Fluxionality† 
Conor Dean,a Sundaram Rajkumar,a Stefan Roesner,a Nessa Carson,b Guy J. Clarkson,a Martin 
Wills,a Matthew Jonesc and Michael Shipman*a
Increased molecular complexity correlates with improved chances of success in the drug development process. Here, a 
strategy for the creation of sp3-rich, non-planar heterocyclic scaffolds suitable for drug discovery is described that obviates 
the need to generate multiple stereogenic centers with independent control. Asymmetric transfer hydrogenation using a 
tethered Ru-catalyst is used to efficiently produce a range of enantiopure cyclic hydrazine building blocks (up to 99% ee). 
Iterative C–N functionalization at the two nitrogen atoms of these compounds produces novel hydrazine and hydrazide 
based chemical libraries. Wide chemical diversification is possible through variation in the hydrazine structure, use of 
different functionalization chemistries and coupling partners, and controlled engagement of each nitrogen of the hydrazine 
in turn. Principal Moment of Inertia (PMI) analysis of this small hydrazine library reveals excellent shape diversity and 
three-dimensionality. NMR and crystallographic studies confirm these frameworks prefer to orient their substituents in 
three-dimensional space under the control of a single stereogenic center through exploitation of the fluxional behavior of 
the two nitrogen atoms. 
1. Introduction
Libraries of small molecules capable of exploring new areas of 
three-dimensional chemical space are of considerable value in 
drug discovery. There is growing evidence that molecular 
complexity, as measured by parameters such as the fraction of 
saturated carbon atoms (Fsp3) and number of stereogenic 
centers, correlates with success rates in drug development.1 
Despite these observations, analysis of current drug-like 
libraries such as the ChEMBL dataset reveals that they 
generally lack shape diversity and three-dimensionality.2 
Hence, there is a need to create new stereochemically-rich 
compound libraries for use in drug-discovery programs that 
overcome these shortcomings. This is a challenging problem 
because it necessitates moving away from well-established 
synthetic methods (e.g. sp2-sp2 cross-couplings) toward 
chemistries that efficiently create non-planar scaffolds.3 In this 
Edge article, we report a way to create novel chemical libraries 
with considerable shape diversity without having to generate 
multiple stereogenic centers with independent control. The 
idea exploits the fluxional behavior of pyramidal nitrogen 
atoms within enantiopure cyclic hydrazines, to create new sp3-
rich heterocyclic frameworks that display their chirality in an 
orchestrated way (Scheme 1).
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Scheme 1. New sp3-rich cyclic hydrazine scaffolds exploiting N-fluxionality.
This approach has a number of attractive features. Cyclic 
hydrazines and hydrazides are well represented in medicinal 
chemistry.4 They are found in many bioactive compounds 
including natural products (e.g. actinoramide A,5 sanglifehrin 
A6), proprietary lead compounds7 and approved drugs (e.g. 
cilazapril8) (Figure 1). Chemical libraries of 1 for discovery 
programs should be readily available by simple, late-stage 
diversification of 2 by iterative functionalization at each 
nitrogen atom. The availability of a plethora of C–N 
functionalization reactions combined with the high 
nucleophilicity of the hydrazine functional group make this 
disconnection highly attractive. By exploiting their dynamic 
behavior, it should be possible to display three substituents (R, 
R1 and R2) attached to carbon and nitrogen very precisely in 
three-dimensional space. Of the four conformational isomers 
1a-d that arise from pyramidal inversion, 1a is expected to be 
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dominant. Typically, cyclic hydrazines adopt an anti-
configuration between the N-substituents to minimize non-
bonded interactions between the lone pairs.9 Thus, the 
formation of 1b and 1c is expected to be disfavored. 
Furthermore, non-bonding interactions between adjacent syn-
substituents should disfavor 1b-d relative to anti,anti-1a. Thus, 
control over only one stereogenic center is needed to produce 
predictable, non-planar frameworks. Finally, further fine-
tuning of the substituent positioning should be possible by 
variation of the ring size.
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Figure 1. Representative examples of bioactive molecules containing cyclic hydrazine 
and hydrazide frameworks (highlighted in red).
2. Results and discussion
2.1. Asymmetric synthesis of cyclic hydrazine frameworks
The first task was to identify an efficient, enantioselective 
route to the hydrazine building blocks, i.e. 2 (Scheme 1). Key 
requirements for such a synthesis were that it: (i) allow the 
introduction of a variety of medicinally-relevant R substituents 
with high levels of enantiocontrol; (ii) provide access to 
different ring sizes; and (iii) yield differentially protected 
hydrazines 2 suitable for facile introduction of the R1 and R2 
groups. While several methods for the asymmetric synthesis of 
cyclic hydrazines exist,10 none met our requirements. 
Consequently, a new two-step approach to 2 was devised 
based upon enantiocontrolled reduction of ketones 3 followed 
by ring closure. By varying the linker length between the 
ketone and hydrazine functional groups, the approach offers 
access to a range of different ring sizes. In choosing a method 
for the reduction, we were drawn to Ru-catalyzed asymmetric 
transfer hydrogenation (ATH) which typically delivers high 
levels of enantioselectivity, requires low catalyst loadings, has 
diverse functional group compatibility and is operationally 
simple to perform.11
Initially, phenyl ketone 5a was prepared by alkylation of 
readily-available, triply-protected hydrazine 4a12 with 2-
bromoacetophenone, followed by Boc deprotection (Table 1). 
Where doubly-protected CbzNHNHTs is used in these 
alkylations, the isomeric products in which the sulfonamide 
and carbamate groups are transposed can also be made (for 
full details, see Supporting Information). Next, ATH reduction 
of 5a was examined by screening a range of chiral diphenyl-
ethylenediamine(DPEN)/Ru(II) catalysts (7a-g) using formic 
acid and triethylamine (5:2 azeotrope) as hydrogen source. 
The majority of these reactions benefited from catalysts that 
were tethered between the arene and DPEN ligand.13 Variation 
in the catalyst structure has a greater impact on catalytic 
activity than enantioselectivity (Table 1), and chlorinated 
solvents were found to be most effective (for details, see 
Supporting Information). Under the optimized conditions, 
ketone 5a was efficiently converted into alcohol R-6a in 97% 
yield and 99% ee using 1 mol% of tethered ruthenium catalyst 
S,S-7c (Table 1, Entry 3). The structure and absolute 
configuration of R-6a were confirmed by X-ray crystallography 
using the Flack parameter (Figure 2, box insert).14 The sense of 
asymmetric induction fits established models,13a indicating that 
the hydrazine plays no active role in catalyst binding.
Table 1. Optimization of Ru-catalyzed asymmetric transfer hydrogenation of ketone 5a.
N
H
N
Ph
O
Ts
Cbz
7a-g (1 mol%)
CH2Cl2
HCO2H:Et3N
23 °C, 24 h
    K2CO3, MeCN, rt
2. CF3CO2H
    CH2Cl2, 0 °C
81%
N
H
N
Ph
OH
Ts
Cbz
4a 6a5a
S,S-7a R,R-7b
PhPh
NH2
Ru
NTs
PhPh
NH2
Ru
NTs
PhPh
N
Ru
NX
Cl
R,R-7e (X = Ms, Y = H)
R,R-7f (X = Ts, Y = OMe)
H
PhPh
N
Ru
NTs
Cl
S,S-7c (n = 1)
S,S-7d (n = 2)
H
R,R-7g
PhPh
N
Ru
NTs
Cl
H
MeO
n
NCbzHN
Ts
Boc
Ph
O
Br
1.
Y
iPr
Cl Cl
 
Entry Catalyst Yield [%]a ee [%]b
1 S,S-7a 86 97 (R)
2 R,R-7b 16 c 91 (S) d
3 S,S-7c 97 99 (R)
4 S,S-7d 7 97 (R)
5 R,R-7e 97 97 (S) d 
6 R,R-7f 80 99 (S) d
7 R,R-7g 16 98 (S) d
a Isolated yield after column chromatography. b Determined by HPLC analysis using 
Chiralpak ADH. c Reaction run for 48 h. d Opposite S-enantiomer produced.
Next, the ATH of a broad range of ketones was examined using 
the optimized conditions (Figure 2). Full details relating to the 
synthesis of substrates 5a-v are provided in the Supporting 
Information. High yields and enantioselectivities were 
achieved in all cases, with variations in the arene, nitrogen 
protecting groups and linker length well tolerated. The sense 
of asymmetric induction in these transformations was made by 
analogy to that seen for R-6a. For 2-substituted aryl derivatives 
5c and 5g, and for 3,5-difluoro derivative 5p, poor levels of 
stereoinduction were obtained using 7c as catalyst. In these 
cases, use of 7f bearing an additional electron-rich methoxy 
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group on the arene significantly improved the 
enantioselectivity.13b
  
O
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n
OH
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Figure 2. Ru-catalyzed ATH of hydrazine-containing ketones. a Using R,R-7f. b ee 
determined after cyclization to 8. c Using R,R-7c.
Ring closure of 6a-v using diethyl azodicarboxylate (DEAD) and 
triphenylphosphine under Mitsunobu conditions provided the 
corresponding cyclic hydrazines 8a-v in good to excellent 
yields (Figure 3). It is possible to replace DEAD with less 
hazardous diisopropyl azodicarboxylate (DIAD), as illustrated 
by the cyclization of 6n to 8n and 6q to 8q with comparable 
efficiency. Furthermore, the methodology can be used to 
make either enantiomer of the cyclic hydrazine by use of 
catalyst R,R-7c or S,S-7c, as demonstrated by the synthesis of 
R-8n and S-8n (Figure 3). Four- to seven-membered rings can 
conveniently be made using this method. In general, little or 
no loss in enantiopurity was seen during cyclization although 
for highly electron-rich thiophene 8m, partial racemization 
(73% ee) was detected. The chemistry can be performed 
preparatively as illustrated by the synthesis of pyrazolidine R-
8j on >5 g scale (see Supporting Information). In this case, the 
catalyst loading was halved to 0.5 mol% in the ATH step. No 
loss in ee was observed at this lower catalyst loading although 
longer reaction times (72 h) were required. For 8d and 8h, the 
structures were verified by XRD to confirm that stereochemical 
inversion occurred during cyclization (see Supporting 
Information).14
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N
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Figure 3. Cyclic hydrazines 8a-v made by Mitsunobu ring closure. a Reaction with DIAD 
in place of DEAD (for full details, see Supporting Information). 
2.2. Synthesis of sp3-rich hydrazine libraries by N-functionalization 
 To determine if these orthogonally-protected cyclic 
hydrazines could be used to generate sp3-rich heterocyclic 
libraries, we explored their functionalization. To make this 
study practicable, a subset of six cyclic hydrazines, namely 8b, 
8j, 8k, and 8t-v, were used. The sequence involved: (i) 
deprotection of the Ts group from the less hindered nitrogen 
using Mg metal; (ii) functionalization by C–N bond formation 
to introduce a variety of R2 fragments; (iii) acidic deprotection 
of the Boc group from the second nitrogen; and (iv) addition of 
the R1 fragment using similar chemistries used in Step (ii) 
(Figure 4). The deprotection reactions were essentially 
quantitative and so product purification was only conducted 
after each C–N functionalization. Conventional acylation and 
reductive amination reactions could be conducted on either 
nitrogen in generally high yields across a range of ring sizes. 
However, high-throughput optimization was required to 
identify general conditions for the Pd-catalyzed Buchwald-
Hartwig arylations (for full details, see Supporting 
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Information). For the introduction of the R2 fragment at the 
least hindered nitrogen on 8i, XPhosPd(crotyl)Cl, NaOtBu and 
toluene proved the most effective combination of catalyst, 
solvent and base. Cross-coupling of the more hindered 
nitrogen in the pyrazolidine ring was achieved with a 
BippyPhosPd(allyl)OTf catalyst to provide 10d and 10g in good 
yields. For other substrates differing in ring size and aryl group, 
Pd(OAc)2 and Xantphos proved to be an effective catalyst 
system. Using this strategy, 14 derivatives (10a-k, 10m-o) were 
produced bearing a diverse set of N- and C-substituents across 
different hydrazine ring sizes. Additionally, by omitting the 
final cross-coupling, scaffolds bearing free amines can also be 
produced (10l, 10p and 10q).15 Four representative examples 
(10b, 10d, 10i, and 10o) confirmed that no erosion of ee 
occurred during these functionalization sequences.
N N
Ts Boc
10e 82%b 84%c
10b 63%d 77%c,e 10d 77%f 77%e,g10a 85%b 82%c
10f 73%b 66%c
10c 85%b 69%c
N
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Ph
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n
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N
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N
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N
N Ph
O
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F
N
N
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N
N
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N
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N
MeO
O
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N
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N
N
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Ph
10k 91%d 80%c
1. Mg, MeOH, rt
2.        addition
(see text)
9a-q 10a-q
R2 R1R23. TFA/CH2Cl2
or HCl/dioxane
4.        addition
(see text)
RRR
O
Cl
Cl
N
N
H Ph
O
N
10l 73%c,i
N
N
Ph
10i 67%h 85%c,e
N
O
OMe
N
N
Ph
10j 67%h 62%d
N
HO
N
N
H Ph
O
AcO
10p 53%c,iN
NO
10n 71%f 50%h
F
Cl
CF3
N
N
N
Ph
O
N
NC
10m 57%h 73%c
N
N
Ph
Ph
O
OMe
10o 90%d 33%c,e
NN
Ph
10q 31%h,i,j
H CF3
• TFA
Figure 4. N-Functionalization of enantioenriched cyclic hydrazines and hydrazides. a 
Isolated yields for two-step syntheses of 9 and 10 respectively. b ArBr, 
XPhosPd(crotyl)Cl (5 mol%), NaOtBu, toluene, 90 °C, 20 h. c RCOCl, DIPEA, CH2Cl2, 0 °C 
to rt, 18 h. d RCHO, NaBH(OAc)3, THF, rt, 20 h. e Enantiomeric excess determined by 
chiral HPLC. f RCOCl, CH2Cl2, rt, 18 h. g ArBr, BippyPhosPd(allyl)OTf (5 mol%), Cs2CO3, 
toluene, 90 °C, 20 h. h ArBr, Pd(OAc)2 (5-10 mol%), Xantphos (10-20 mol%), NaOtBu, 
toluene, 90 °C, 20 h. I Yield over 3 steps after Boc removal. j The Boc and Ts groups are 
transposed in the starting material 8b.
2.3. Molecular shape and dynamics of sp3-rich hydrazine scaffolds
The shapes of the cyclic hydrazines have been studied using a 
combination of computational and spectroscopic tools. To 
assess the three-dimensionality of 10a-q in the 17-member 
hydrazine library, the LLAMA package16 was used to compute 
and display their principal moments of inertia (PMI) (Figure 
5).17 This tool randomly selects a number of 3D-conformers for 
each molecule, minimizes their energy and selects the lowest-
energy one. The selected minimum energy conformers of 10a-
q are provided in the Supporting Information. LLAMA then 
calculates the moments of inertia in the x, y and z axes. The 
PMI I1 coordinates are calculated by dividing inertia(x) by 
inertia(z). The I2 coordinates are calculated by dividing 
inertia(y) by inertia(z). This plot confirms that members of this 
small hydrazine library possess excellent shape diversity and 
three-dimensionality compared with conventional databases.2 
The wide distribution of the heterocycle frameworks within 
this plot suggests that it is the nature of the appended 
substituents (R, R1 and R2), rather than the size of the 
hydrazine ring, that has the greatest influence on their overall 
shape (Figure 5). 
Figure 5. Principal moments of inertia (PMI) plot of hydrazines 10a-q indicating their 
molecular shapes. Mean PMI indicated ().  
Next, the solution and solid-state structures of representative 
cyclic hydrazines and hydrazides were determined. A total of 
eight derivatives were studied by single crystal X-ray 
diffraction (XRD).14 The ORTEP depictions of 8d, 9m, 10a and 
10b are given in Figure 6. For four-membered 8d and five-
membered 10a and 10b, the anti,anti-configuration of the R, 
R1 and R2 substituents is apparent. For hexahydropyridazine 
9m where the conformational flexibility of the ring becomes 
more important, the R group still exerts a strong influence 
leading to a highly non-planar structure in which the R, R1 and 
R2 substituents are displayed in a predictable way on opposite 
faces of the hydrazine ring. The crystallographic data also 
provide insight into the extent of pyramidalization of the two 
nitrogen atoms within the ring,18 a factor influencing both their 
shapes and fluxional behavior. The values for the 
pyramidalization of each nitrogen are given in Figure 6, with 
larger values indicating more sp3-character at the nitrogen 
center.   
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8d
N1 = 27.6°, N2 = 34.5°
10a
N1 = 28.0°, N2 = 15.0°
9m
N1 = 4.9°, N2 = 10.7°
10b
N1 = 36.4°, N2 = 2.8°
Figure 6. Representative XRD structures of the cyclic hydrazines with measured values 
for the pyramidalization of the two ring nitrogens (N1 and N2).18
Next, the solution-state structure of 10b was determined in 
C6D6 at 343 K by 1H NOESY spectroscopy (600 MHz). These 
conditions were used to produce a single set of well resolved 
signals. The solution structure was assigned on the basis of 
NOESY cross-peaks between the ortho-hydrogens of the 
phenyl ring (H-3) and the methylene hydrogens of the isobutyl 
group (H-9 and possibly H-10) consistent with these 
substituents being on the same side of the hydrazine ring 
(Figure 7b). Furthermore, the observation of a NOESY cross-
peak between H-2 and H-8, and between H-6 and H-8 places 
all these atoms on the same side of the molecule and on the 
opposite face to the phenyl group (Figure 7c). On this basis we 
assign an anti,anti-configuration to 10b in solution (Figure 7a), 
similar to the solid-state structure (Figure 6).14
 
Figure 7. Solution-state structure of 10b derived by 1H-1H NOESY spectroscopy (600 
MHz, C6D6, 343 K): (a) anti,anti-representation of 10b with key NOEs indicated (red 
arrows). (b) Expansion of the NOESY spectrum highlighting cross-peaks between H-3 
and H-9 and possibly H-10. (c) Expansion of the NOESY spectrum highlighting key cross-
peaks between H-8 and H-2, and H-8 and H-6.   
To explore the fluxional behavior of the cyclic hydrazines, 
variable temperature 1H NMR studies were conducted using 
10a and 10b. For 10a, the 1H NMR spectrum resolved into two 
sharp sets of signals at 233 K in CDCl3, indicating the presence 
of two conformational isomers in a 56:44 ratio. In contrast, 
10b exists predominately as a single conformational isomer at 
233 K in CDCl3 although small amounts of two additional 
isomers are seen (84:11:5). Evidently, the fluxional behavior is 
highly dependent on the nature of the N-substituents. This is 
consistent with changes in the extent of N-pyramidalization 
seen in the solid-state (Figure 6). Using the resolved methyl 
singlets of 10a, we were able to determine the barrier to 
interconversion of the two isomers at coalescence (Tc = 258 K, 
G‡ = 54 kJ mol-1, see Supporting Information). The question 
arises as to whether the two isomers come from fluxionality at 
the hydrazine centers (Scheme 1), or from a process such as 
amide bond rotation within anti,anti-10a? On the available 
evidence, we suggest that only amide rotamers are being 
observed i.e. A and B (Scheme 2). First, whilst low temperature 
NOESY experiments did not allow us to fully deduce the 
solution-state structure of 10a, we did observe a NOESY cross-
peak between the methine hydrogen at H-3 and the ortho-
hydrogens of the COAr group for A but not B consistent with 
this assignment. Secondly, the measured interconversion 
barrier is more consistent with that of an amide bond rotation 
in similar systems. For example, both types of fluxionality 
operate concurrently in 11 with a lower barrier for rotation 
about the N–CO bond than ring inversion (box insert, Scheme 
2).19 Finally, the near equal population of A and B is 
inconsistent with N-inversion as 1b-d are expected to be 
higher energy species due to unfavorable non-bonded 
interactions (Scheme 1). Although N-fluxionality is not 
operating in 10a, the observation of a third set of signals for 
10b at low temperature, suggests that conformational isomers 
arising from N-inversion are accessible for some systems, 
albeit in low concentrations.  
  
Scheme 2. Likely origin of fluxional behaviour seen in 10a.
3. Conclusions
An efficient synthesis of differentially-protected cyclic 
hydrazines containing an adjacent stereogenic carbon atom 
has been devised using ATH as the key step. Commercially 
available tethered Ru-catalyst 7c, available in both 
enantiomeric forms, proved highly effective for the 
introduction of the asymmetric center by ketone reduction. In 
the few cases where low enantioselectivity was seen in the 
ATH, tethered catalyst 7f gave further improvements. The 
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methodology was used to make 22 different cyclic hydrazines 
in up to 99% ee, through variation in ring size (4- to 7-
membered rings), C-3 substituents and nitrogen protecting 
groups. The chemistry is operationally simple and can be 
performed on a preparative scale. Chemical library 
construction is possible from these hydrazines by iterative C–N 
bond formation. Wide chemical diversification is possible 
through variation in the hydrazine structure, use of different 
functionalization chemistries and coupling partners, and 
controlled engagement of each nitrogen of the hydrazine in 
turn. Principal moment of inertia (PMI) analysis revealed 
excellent shape diversity and three-dimensionality within the 
assembled library, indicating their potential value in drug 
discovery. The preference for the molecules to adopt anti,anti-
orientations of the three stereocenters was established using a 
combination of XRD and NMR spectroscopy. The fluxional 
behavior of these compounds was further explored by VT-
NMR and low temperature NOESY experiments, from which 
useful insights have emerged about how the molecules sample 
chemical space. Future work will examine the feasibility of 
making larger chemical libraries based on these non-planar 
scaffolds and the exploitation of this chemistry in drug 
discovery programs.
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